Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
Open Access
- 21 February 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-3
- https://doi.org/10.1038/s41392-020-0127-9
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81630102, 81803833)
This publication has 11 references indexed in Scilit:
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injuryThe Lancet, 2020
- Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, ChinaJournal of Medical Virology, 2020
- Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumoniaMedicine, 2019
- Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching studyIntensive Care Medicine, 2018
- Steroids for sepsis: yes, no or maybeJournal of Thoracic Disease, 2018
- Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Effect of low‐to‐moderate‐dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumoniaInfluenza and Other Respiratory Viruses, 2017
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016Critical Care Medicine, 2017
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome?The American Journal of Surgery, 1995